Key result
Ryanodine receptors are key ion channels for intracellular calcium release, and pharmacological agents targeting them have potential as therapeutic agents for skeletal and cardiac muscle diseases.
Provides an overview of ryanodine receptor pharmacology and highlights the potential of RyR-focused therapeutic agents for cardiac and skeletal muscle diseases.
Ryanodine receptors (RyR) are cation‐selective, ligand‐modulated, ion channels that provide a pathway for the regulated release of Ca 2+ from intracellular reticular storage organelles to initiate a wide variety of cellular processes. In addition to regulation by endogenous ligands, the function of RyR can be altered by many pharmacological agents. Some of these have been used to establish the contribution of RyR‐mediated Ca 2+ release to diverse signaling processes. Altered RyR function also plays a role in the development of diseases of both skeletal and cardiac muscles, hence both new and established compounds have potential as RyR‐focussed therapeutic agents. WIREs Membr Transp Signal 2012, 1:383–397. doi: 10.1002/wmts.34 For further resources related to this article, please visit the WIREs website .
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2012) conducted a review in Diseases of skeletal and cardiac muscles. Pharmacological agents targeting ryanodine receptors was evaluated. Ryanodine receptors are key ion channels for intracellular calcium release, and pharmacological agents targeting them have potential as therapeutic agents for skeletal and cardiac muscle diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: